Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.[1] It is being developed by Orexigen Therapeutics. It has undergone phase 2 tests and is waiting for phase 3 testing to commence. The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.[2] When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo.

Empatic was called Excalia before its name was changed.[3]